GlassScriptPhysician profile
Osman Ahmed
NPI 1427021310
$14,683.93
in general payments reported to CMS, 2019-2025
41 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,270 · 2020: $1,077 · 2021: $2,576 · 2022: $2,374 · 2023: $1,503 · 2024: $769 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Travel and Lodging: $468 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.69 |
| Travel and Lodging | $468.16 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $4,400.00 | 2019 | |
| Boston Scientific Corporation | $1,199.38 | 2021-2024 | Watchman Flx |
| Medical Device Business Services, INC. | $1,054.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $858.49 | 2019-2023 | Xarelto |
| Medtronic, INC. | $646.55 | 2023 | Intellis Adaptivestim, Hawkone, Riptide |
| Argon Medical Devices, INC. | $569.78 | 2020-2023 | Ivcf |
| Amgen INC. | $567.72 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $515.88 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $500.58 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $424.87 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $412.92 | 2020-2025 | |
| Astellas Pharma US INC | $385.43 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $307.25 | 2019-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $289.86 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.72 | 2021-2024 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $262.54 | 2019-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $259.90 | 2020-2024 | Farxiga, Epanova, Wainua |
| Siemens Medical Solutions USA, INC. | $245.52 | 2025 | |
| Novo Nordisk INC | $226.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Baxter Healthcare | $144.62 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Nevro Corp. | $144.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $139.98 | 2022-2025 | Amvuttra |
| Terumo Medical Corporation | $128.29 | 2025 | Azur Cx Detachable, Navicross |
| Bayer Healthcare Pharmaceuticals INC. | $88.95 | 2021 | |
| Penumbra, INC. | $85.00 | 2023 | Indigo System |
| Cook Medical LLC | $81.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $71.63 | 2022-2023 | |
| Abiomed | $64.50 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $57.44 | 2024 | Arcalyst |
| Abbott Laboratories | $40.87 | 2021-2024 | Aveir |
| Philips North America LLC | $39.52 | 2020 | |
| W. L. Gore & Associates, INC. | $33.83 | 2022 | |
| Akcea Therapeutics, INC. | $30.01 | 2019-2021 | |
| Inspire Medical Systems, INC. | $26.26 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $20.01 | 2023 | Inpefa |
| United Therapeutics Corporation | $16.14 | 2019 | |
| Bardy Diagnostics, INC. | $16.00 | 2022 | |
| Cleerly, INC. | $15.21 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Biotronik INC. | $14.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.15 | 2021 | |
| Allergan, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.